Is PharmaResearch Co., Ltd. a good investment? PharmaResearch Co., Ltd. (214450.KQ) is currently trading at 298000.00 KRW. Market analysts have a consensus price target of 516214.28 KRW. This suggests a potential upside from current levels.
Earnings Schedule: PharmaResearch Co., Ltd. is expected to release its next earnings report on Aug. 18, 2026.
For income investors, PharmaResearch Co., Ltd. pays a dividend yield of 1.25%. With a payout ratio of 23%, the dividend appears sustainable.
Yes, it pays an annual dividend of 1100.00 KRW (1.25% yield).
PharmaResearch Co., Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Aug. 18, 2026.
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.
| Year | Total Dividends |
|---|---|
| ▸2027 |
1,100.00 KRW
|
| April 19, 2027 (estimated) | 1,100.0000 |
| ▸2026 |
1,100.00 KRW
|
| April 17, 2026 | 1,100.0000 |
| ▸2024 |
1,760.00 KRW
|
| Dec. 27, 2024 | 1,100.0000 |
| April 18, 2024 | 660.0000 |
| ▸2023 |
660.00 KRW
|
| April 14, 2023 | 660.0000 |
| ▸2021 |
600.00 KRW
|
| Dec. 29, 2021 | 600.0000 |
| ▸2020 |
500.00 KRW
|
| Dec. 29, 2020 | 500.0000 |
| ▸2019 |
300.00 KRW
|
| Dec. 27, 2019 | 300.0000 |
| ▸2018 |
300.00 KRW
|
| Dec. 27, 2018 | 300.0000 |
| ▸2017 |
300.00 KRW
|
| Dec. 27, 2017 | 300.0000 |
| ▸2016 |
300.00 KRW
|
| Dec. 28, 2016 | 300.0000 |
| ▸2015 |
200.00 KRW
|
| Dec. 29, 2015 | 200.0000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| PharmaResearch Co., Ltd. | Apr 17, 2026 | Paid | 1100.0 KRW |
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 30, 2025 | 0.742794 |
Community Discussion